Statistics on Biotechnology Use  
Results by fields of operation
Business Sector Biotechnology indicators by company size. 
Unidades: specified in variables

,Fewer than 250 employees,250 or more employees,Total 2021,
No. of companies carrying out R&D in Biotechnology,1.226,122,1.348,
%Companies according to biotechnology used: Genetic code,30,5,36,31,
%Companies according to biotechnology used: Functional units,37,6,46,7,38,4,
%Companies according to biotechnology used: Cellular and tissue culturing and engineering,20,5,33,6,21,7,
%Companies according to biotechnology used: Bioprocesses,48,6,68,1,50,3,
%Companies according to biotechnology used: Sub-cellular organisms,7,2,18,8,2,
%Companies according to biotechnology used: Bio-computing,24,25,4,24,1,
%Companies according to biotechnology used: Nanobiotechnology,11,8,11,5,11,8,
%Companies according to biotechnology used: Other,17,10,7,16,4,
Companies in which biotechnology activities are: Main and/or exclusive,639,22,661,
Companies in which biotechnology activities are: A secondary line of business,166,22,188,
Companies in which biotechnology activities are: A tool necessary for production,421,78,500,
%Company by field(s) of ultimate application of biotechnology use: Human Health,45,8,45,9,45,8,
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture,15,6,11,5,15,3,
%Company by field(s) of ultimate application of biotechnology use: Food products,31,5,32,31,5,
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production,24,1,19,6,23,7,
%Company by field(s) of ultimate application of biotechnology use: Environment,16,11,5,15,5,
%Company by field(s) of ultimate application of biotechnology use: Industry,13,4,13,1,13,4,
Personnel in R&D in biotechnology (no. of persons),10.473,5.271,15.744,
Personnel in R&D in biotechnology (no. of persons): Research personnel,5.914,2.465,8.380,
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel,4.558,2.806,7.364,
Personnel in R&D in biotechnology (no. of persons). Women,5.482,3.242,8.725,
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel,3.094,1.426,4.521,
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel,2.388,1.816,4.204,
Personnel in R&D in biotechnology (FTE),7.354,4,4.168,8,11.523,2,
Personnel in R&D in biotechnology (FTE): Research personnel,4.402,9,1.938,6,6.341,6,
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel,2.951,5,2.230,1,5.181,6,
Personnel in R&D in biotechnology (FTE). Women,3.909,3,2.643,4,6.552,7,
Personnel in R&D in biotechnology (FTE). Women: Research personnel,2.305,8,1.158,6,3.464,4,
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel,1.603,5,1.484,8,3.088,3,
Internal expenditure on R&D (thousands of euros),648.976,388.911,1.037.887,
1) By nature of the expense: Current expenses,577.758,361.713,939.471,
1.1) Remuneration to research personnel,213.250,108.275,321.525,
1.2) Remuneration to technical and auxiliary personnel,104.359,90.297,194.656,
1.3) Other current expenses,260.148,163.141,423.290,
2) By nature of the expense: Capital expenses,71.218,27.197,98.416,
2.1) Land and buildings,8.904,1.246,10.150,
2.2) Equipment and instruments,48.703,23.835,72.538,
2.3) Acquisition of specific R&D software,3.749,1.963,5.713,
2.4) Otros productos de propiedad intelectual específicos para I+D,9.862,153,10.015,
1.1) By origin of the funds: Own funds,428.118,282.919,711.037,
1.2) By origin of the funds: From companies,87.264,34.331,121.595,
1.3) By origin of the funds: Public Administration funds,81.113,26.309,107.422,
1.4) By origin of the funds: From Universities,192,0,192,
1.5) By origin of the funds: From non profit private institutions,1.543,9.213,10.756,
1.6) By origin of the funds: Foreign funds,50.745,36.139,86.884,
Purchase of R&D services in biotechnology (thousands of euros),77.001,68.440,145.440,
Purchase of R&D services in biotechnology (thousands of euros): In Spain,54.755,41.115,95.870,
Purchase of R&D services in biotechnology (thousands of euros): Abroad,22.246,27.324,49.570,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital,41,6,21,3,39,8,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information,12,5,12,3,12,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources,18,8,14,8,18,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain,10,9,14,8,11,2,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets,15,9,12,3,15,6,
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels,17,11,5,16,5,
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception,16,3,13,9,16,1,
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements,40,8,32,8,40,
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost,54,9,43,4,53,9,
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting,21,7,18,8,21,5,
% Companies with income of an international origin related to biotechnological activities,22,8,16,4,22,2,
% Turnover representing income of an international origin related to biotechnological activities,9,1,0,8,1,9,
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU,57,9,78,65,5,
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries,42,1,22,34,5,
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services,93,7,74,2,86,3,
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain,5,2,23,6,12,2,
% Income of an international origin related with activities according to the classification: Operating source abroad,0,5,2,1,1,1,
% Income of an international origin related with activities according to the classification: Other,0,6,0,0,4,
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute